Sterile injectables · Contract manufacturing in India

D-Panthenol 50 mg, Methylcobalamin 1500 mcg, Nicotinamide 100 mg, Pyridoxine 100 mg, Thiamine 100 mg / 2 ml Liquid injectables

Request manufacturing feasibility

Discuss third-party manufacturing of D-Panthenol 50 mg, Methylcobalamin 1500 mcg, Nicotinamide 100 mg, Pyridoxine 100 mg, Thiamine 100 mg / 2 ml Liquid injectables with Walter Healthcare, India. Share your target market, required container count and fill volume, packaging and launch timeline for a product-specific quotation.

Catalogue reference
WH-1834
Composition and strength
D-Panthenol 50 mg, Methylcobalamin 1500 mcg, Nicotinamide 100 mg, Pyridoxine 100 mg, Thiamine 100 mg / 2 ml
Dosage form
Liquid injectables
Indicative administration route
Parenteral
Therapeutic navigation area
Nutrition & supportive care
Pharmacological class
Haematinic & nutritional supplement
Manufacturing stream
Non-beta-lactam

Catalogue details support an initial B2B discussion. Walter confirms the applicable unit, current licence scope, formula, target market and commercial feasibility before making a commitment.

Clinical reference

Mechanism and pharmacokinetics.

Explore the published evidence for the ingredients in D-Panthenol 50 mg, Methylcobalamin 1500 mcg, Nicotinamide 100 mg, Pyridoxine 100 mg, Thiamine 100 mg / 2 ml Liquid injectables. Each reference identifies its source formulation and study context. Ingredient studies describe the named reference product; they do not establish the pharmacokinetics, clinical suitability or bioequivalence of this finished formulation.

How to read our product information and sources ↗

Ingredient-level reference

Methylcobalamin (mecobalamin injection)

Reference for: Methylcobalamin. Source presentation: INJECTION. Source route: intramuscular; intravenous.

Mechanism of action

Mecobalamin is a coenzyme form of vitamin B12 that participates in methionine-synthase-mediated transfer of methyl groups during conversion of homocysteine to methionine. The reference separates this biochemical role from experimental nerve-cell and animal findings.

Pharmacokinetics

In twelve healthy men given 500 micrograms, total serum B12 peaked at approximately 0.9 hours after intramuscular administration and immediately to 3 minutes after intravenous administration. The reported half-lives were 29.0 and 27.1 hours respectively. These measurements concern total serum B12 after accounting for endogenous concentrations, not a selective assay of unchanged methylcobalamin. They do not establish the kinetics of a 1,500- or 2,500-microgram combination product.

Ingredient-level summary of the cited reference product. Study formulation, route, strength and population govern interpretation; these data do not establish pharmacokinetics or bioequivalence for Walter's formulation or fixed combination.

Source: Malaysia NPRA / Eisai: Methycobal Injection 500 micrograms/mL, March 2024

Reference accessed .

Ingredient-level reference

Nicotinamide (intravenous vitamin reference)

Reference for: Nicotinamide. Source presentation: MULTIVITAMIN INFUSION. Source route: intravenous.

Mechanism of action

Nicotinamide contributes to NAD and NADP coenzymes involved in cellular oxidation-reduction reactions.

Pharmacokinetics

The intravenous multivitamin reference describes plasma vitamin B3 in acid or amide forms and urinary elimination as unchanged substance or metabolites. It does not provide a nicotinamide-specific half-life or validate another injection mixture.

Ingredient-level summary of the cited reference product. Study formulation, route, strength and population govern interpretation; these data do not establish pharmacokinetics or bioequivalence for Walter's formulation or fixed combination.

Source: France ANSM: Cernevit, nicotinamide component, sections 5.1–5.2

Reference accessed .

Ingredient-level reference

Dexpanthenol (intravenous vitamin reference)

Reference for: D-Panthenol. Source presentation: MULTIVITAMIN INFUSION. Source route: intravenous.

Mechanism of action

The reference supplies vitamin B5 as dexpanthenol. Pantothenic acid is a precursor of coenzyme A in carbohydrate and lipid metabolism.

Pharmacokinetics

The intravenous reference describes vitamin B5 in plasma and red cells as free pantothenic acid or coenzyme A, with urinary elimination. These are vitamin disposition data, not a measured unchanged-dexpanthenol half-life or evidence for intramuscular kinetics.

Ingredient-level summary of the cited reference product. Study formulation, route, strength and population govern interpretation; these data do not establish pharmacokinetics or bioequivalence for Walter's formulation or fixed combination.

Source: France ANSM: Cernevit, dexpanthenol/vitamin B5 component, sections 5.1–5.2

Reference accessed .

Prescribing-label excerpts

Thiamine Hydrochloride

Reference for: Thiamine. Source presentation: injection, solution. Source route: intramuscular; intravenous.

The source label presents its clinical-pharmacology findings together. These selected passages retain the source’s study context; the full label provides the complete discussion.

Clinical pharmacology

The water soluble vitamins are widely distributed in both plants and animals. They are absorbed in man by both diffusion and active transport mechanisms. These vitamins are structurally diverse (derivatives of sugar, pyridine, purines, pyrimidine, organic acid complexes and nucleotide complex) and act as coenzymes, as oxidation-reduction agents, possibly as mitochondrial agents. Metabolism is rapid, and the excess is excreted in the urine.

Thiamine is distributed in all tissues. The highest concentrations occur in liver, brain, kidney and heart. When thiamine intake is greatly in excess of need, tissue stores increase two to three times. If intake is insufficient, tissues become depleted of their vitamin content. Absorption of thiamine following IM administration is rapid and complete.

Thiamine combines with adenosine triphosphate (ATP) to form thiamine pyrophosphate, also known as cocarboxylase, a coenzyme. Its role in carbohydrate metabolism is the decarboxylation of pyruvic acid in the blood and α-ketoacids to acetaldehyde and carbon dioxide. Increased levels of pyruvic acid in the blood indicate vitamin B1 deficiency.

The requirement for thiamine is greater when the carbohydrate content of the diet is raised. Body depletion of vitamin B1 can occur after approximately three weeks of total absence of thiamine in the diet.

Selected passages from the cited U.S. prescribing label. The studies concern the source product and populations named in each passage; they do not establish Walter-product bioequivalence, an approved indication, or the kinetics of another fixed combination. Tables and the full prescribing information remain available in the source.

Source: DailyMed: Thiamine Hydrochloride — injection, solution

Reference accessed . Label revision: 2026-07-31.

Prescribing-label excerpts

Pyridoxine Hydrochloride

Reference for: Pyridoxine. Source presentation: injection, solution. Source route: intramuscular; intravenous.

The source label presents its clinical-pharmacology findings together. These selected passages retain the source’s study context; the full label provides the complete discussion.

Clinical pharmacology

Natural substances that have vitamin B 6 activity are pyridoxine in plants and pyridoxal or pyridoxamine in animals. All 3 are converted to pyridoxal phosphate by the enzyme pyridoxal kinase. The physiologically active forms of vitamin B 6 are pyridoxal phosphate (codecarboxylase) and pyridoxamine phosphate. Riboflavin is required for the conversion of pyridoxine phosphate to pyridoxal phosphate.

Vitamin B 6 acts as a coenzyme in the metabolism of protein, carbohydrate, and fat. In protein metabolism, it participates in the decarboxylation of amino acids, conversion of tryptophan to niacin or to serotonin (5-hydroxtryptamine), deamination, and transamination and transulfuration of amino acids. In carbohydrate metabolism, it is responsible for the breakdown of glycogen to glucose-1-phosphate.

The total adult body pool consists of 16 to 25 mg of pyridoxine. Its half-life appears to be 15 to 20 days. Vitamin B 6 is degraded to 4-pyridoxic acid in the liver. This metabolite is excreted in the urine.

The need for pyridoxine increases with the amount of protein in the diet. The tryptophan load test appears to uncover early vitamin B 6 deficiency by detecting xanthinurea. The average adult minimum daily requirement is about 1.25 mg. The ‘‘Recommended Dietary Allowance’’ of the National Academy of Sciences is estimated to be as much as 2.2 mg for adults and 2.5 mg for pregnant and lactating women. The requirements are more in persons having certain genetic defects or those being treated with isonicotinic acid hydrazide (INHJ) or oral contraceptives.

Selected passages from the cited U.S. prescribing label. The studies concern the source product and populations named in each passage; they do not establish Walter-product bioequivalence, an approved indication, or the kinetics of another fixed combination. Tables and the full prescribing information remain available in the source.

Source: DailyMed: Pyridoxine Hydrochloride — injection, solution

Reference accessed . Label revision: 2024-10-15.

Manufacturing & packaging brief

Plan the liquid-injectable presentation.

Use this preparation guide for D-Panthenol 50 mg, Methylcobalamin 1500 mcg, Nicotinamide 100 mg, Pyridoxine 100 mg, Thiamine 100 mg / 2 ml Liquid injectables. These are the decisions to resolve with the technical team before a site, process and commercial scope are confirmed.

Presentation & formulation

Confirm concentration, fill volume, route and whether the proposed container is single-dose or multidose. Identify the formulation and transfer information available.

Quality & technical transfer

Ask for review of the sterile-process strategy, applicable sterility, endotoxin and particulate controls, analytical methods and container-closure integrity requirements.

Review the technical documents

Packaging configuration

Specify ampoule, vial or other proposed container, contact materials, closure and secondary pack. Confirm equipment and facility fit for that configuration.

Explore packaging options

Details to confirm for this record

Full composition
Keep all named components and their individual amounts together in the specification. Ingredient substitutions, omissions and changed ratios require a separate formula and permission review.
Concentration and pack size
The record includes a concentration or percentage expression. Confirm its complete basis, then specify the finished fill volume or weight separately. Do not treat pack size as the strength.

Quantities, MOQ & lead time

For D-Panthenol 50 mg, Methylcobalamin 1500 mcg, Nicotinamide 100 mg, Pyridoxine 100 mg, Thiamine 100 mg / 2 ml Liquid injectables (WH-1834), state the container count and fill volume, target market and reorder forecast. MOQ and lead time depend on the assessed formula, process, components, testing and project readiness; request those terms in writing.

Discuss this manufacturing brief

Explore the context

Build the right manufacturing brief.

Common questions

Before you request a quotation.

D-Panthenol 50 mg, Methylcobalamin 1500 mcg, Nicotinamide 100 mg, Pyridoxine 100 mg, Thiamine 100 mg / 2 ml Liquid injectables

What is listed in the catalogue?

The catalogue lists D-Panthenol 50 mg, Methylcobalamin 1500 mcg, Nicotinamide 100 mg, Pyridoxine 100 mg, Thiamine 100 mg / 2 ml as liquid injectables in its nutrition & supportive care navigation area and non-beta-lactam manufacturing stream.

How do you confirm manufacturing availability?

Send Walter your requirement for D-Panthenol 50 mg, Methylcobalamin 1500 mcg, Nicotinamide 100 mg, Pyridoxine 100 mg, Thiamine 100 mg / 2 ml Liquid injectables. The team reviews the applicable product permission and unit, formulation and equipment fit, testing, packaging and production schedule before confirming the manufacturing scope in writing. Request the relevant product and facility documents with your enquiry.

What do I need for a quotation?

Share the exact composition and strength, liquid injectables presentation, target market, initial quantity, preferred pack and timing. Identify whether this is a new product, development brief or transfer.

The quotation must confirm MOQ, inclusions, prerequisites and lead time for the proposed product and site.

What is needed for Indian and export markets?

For India, share the intended brand or institutional supply requirement, pack sizes, initial order quantity and artwork needs for D-Panthenol 50 mg, Methylcobalamin 1500 mcg, Nicotinamide 100 mg, Pyridoxine 100 mg, Thiamine 100 mg / 2 ml Liquid injectables. Confirm the applicable product permission, manufacturing unit and labelling requirements with the team.

For export, identify each destination country, proposed pack, language and registration or dossier requirements. Ask which product-specific quality and stability documents are available. Container compatibility and destination-market requirements need review; a catalogue record does not establish export registration or a shelf-life commitment.

How do I submit my enquiry?

Use the product-specific enquiry button to carry this composition and dosage form into the form. After a successful submission, a receipt reference confirms that your brief has been saved for review. Use the RFQ checklist to prepare the remaining details.

Technical document review

Which documents can I ask Walter to review?

Ask about manufacturing and packing records, specifications, analytical methods, Certificates of Analysis (COA), stability evidence, the Process Validation Protocol (PVP) and Process Validation Report (PVR). The wider checklist below covers supplier qualification, technical transfer and ongoing supply.

View the full document checklist 14 review areas
Site, licence and audit scope
Manufacturing licence, applicable product permissions, GMP certificates, Site Master File, supplier-qualification questionnaire and relevant audit responses.
Manufacturing, packing and batch release
Master Formula Record (MFR), master packing instructions, Batch Manufacturing Record (BMR), Batch Packing Record (BPR), reconciliation and authorised release records.
Process validation and continued verification
Process Validation Protocol (PVP), Process Validation Report (PVR), process performance qualification documents and continued process verification trends.
Equipment, facilities and utilities
Validation Master Plan (VMP), user requirements, DQ/IQ/OQ/PQ records, calibration and maintenance evidence for relevant equipment and utilities.
Cleaning, carryover and hold times
Cleaning Validation Protocol (CVP), Cleaning Validation Report (CVR), residue limits, recovery studies and applicable clean, dirty and process hold-time studies.
Specifications and analytical evidence
Specifications, Method of Analysis (MOA), Standard Testing Procedure (STP), Certificates of Analysis (COA), analytical validation, verification and method-transfer records.
Stability, packaging and transport
Stability protocols/reports, ongoing stability commitments, pack specifications, approved artwork, compatibility and applicable packaging or transport studies.
Development and technology transfer
Development report, technology-transfer protocol/report, gap assessment, control strategy, critical quality attributes and critical process parameters.
Quality reviews, investigations and changes
Product Quality Review (PQR) / Annual Product Review (APR), deviations, CAPA, change control, OOS/OOT trends, complaints, recalls and relevant SOP/training records.
Material suppliers and impurity risks
API/excipient supplier qualification, traceability, material COAs, relevant origin declarations and impurity risk assessments with supporting tests.
Sterile-product evidence, where applicable
Contamination Control Strategy (CCS), media-fill/aseptic simulation reports, sterilisation and filtration validation, environmental monitoring, sterility/endotoxin and container-closure integrity evidence.
Computerised systems and data integrity
Computerised-system validation, access controls, audit-trail review, backup/restore checks and relevant data-integrity procedures.
Market-specific regulatory support
Applicable dossier sections, API master-file/CEP support, bioequivalence or biowaiver evidence and Certificate of a Pharmaceutical Product (CPP/CoPP), where required and available.
Quality agreement and access arrangements
Quality/technical agreement covering responsibilities, release, changes, subcontracting, investigations, complaints, recalls, audits and document access.

Agree the list for the exact product, site, process, pack, market and project stage. QA confirms what exists, applies and may be shared; some records may require an NDA, redaction or controlled review. See document definitions and review guidance.

Important qualification

This B2B catalogue record is not proof of current approval or confirmation that D-Panthenol 50 mg, Methylcobalamin 1500 mcg, Nicotinamide 100 mg, Pyridoxine 100 mg, Thiamine 100 mg / 2 ml Liquid injectables is available for sale. It is not prescribing information or patient advice. Any Drugs Rules status, current approval, exemption, applicable unit, licence scope, formulation, claims, brand use, destination-market registration and commercial feasibility require documentary verification and Walter's written confirmation. Read the full regulatory disclaimer.

Composition and classification are taken from Walter's product catalogue. The manufacturing guide helps buyers prepare a technical brief. Clinical references, where shown, describe the cited product and study. Manufacturing guide updated .